Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia

Bibliography

• Robert Roskoski J. "Protein kinase,". AccessScience. ©McGraw-Hill Co.; 2008
   Google Scholar
• Manning G, Whyte DB, Martinez R, The protein kinase complement of the human genome. Science 2002;298:1912-34
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A, Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-18
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118:4313-20
   PubMed Web of Science ®Google Scholar
• Takata M, Sabe H, Hata A, Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 1994;13:1341-9
   PubMed Web of Science ®Google Scholar
• Kurosaki T. Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol 1999;17:555-92
   PubMed Web of Science ®Google Scholar
• Jiang A, Craxton A, Kurosaki T, Clark EA. Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med 1998;188:1297-306
   PubMed Web of Science ®Google Scholar
• Fu C, Turck CW, Kurosaki T, Chan AC. BLNK: a central linker protein in B cell activation. Immunity 1998;9:93-103
   PubMed Web of Science ®Google Scholar
• Marshall AJ, Niiro H, Yun TJ, Clark EA. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000;176:30-46
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Iwamatsu A, Ishiai M, Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK–functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Blood 1999;94:2357-64
   PubMed Web of Science ®Google Scholar
• Contri A, Brunati AM, Trentin L, Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369-78
   PubMed Web of Science ®Google Scholar
• Tibaldi E, Brunati AM, Zonta F, Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2011;25:1768-81
   Google Scholar
• Motiwala T, Datta J, Kutay H, Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib. J Cell Biochem 2010;110:846-56
   PubMed Web of Science ®Google Scholar
• Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008;1784:56-65
   PubMed Web of Science ®Google Scholar
• Hussein K, von Neuhoff N, Busche G, Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies. Ann Hematol 2009;88:1059-67
   PubMed Web of Science ®Google Scholar
• Trentin L, Frasson M, Donella-Deana A, Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 2008;112:4665-74
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Altavilla G. Dasatinib induces a response in chronic lymphocytic leukemia. Blood 2009;113:498
   PubMed Web of Science ®Google Scholar
• Amrein L, Panasci L, Gibson SB, Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro. Br J Haematol 2009;147:396-8
   PubMed Web of Science ®Google Scholar
• Veldurthy A, Patz M, Hagist S, The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443-52
   PubMed Web of Science ®Google Scholar
• Amrein PC, Attar EC, Takvorian T, Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977-86
   PubMed Web of Science ®Google Scholar
• Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights 2007;2:93-106
   PubMedGoogle Scholar
• Kadia T, Delioukina ML, Kantarjian H, (ASH abstract). Blood 2011;118:2858
   Google Scholar
• Turner M, Mee PJ, Costello PS, Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298-302
   PubMed Web of Science ®Google Scholar
• Cheng AM, Rowley B, Pao W, Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995;378:303-6
   PubMed Web of Science ®Google Scholar
• Young RM, Hardy IR, Clarke RL, Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009;113:2508-16
   PubMed Web of Science ®Google Scholar
• Semichon M, Merle-Beral H, Lang V, Bismuth G. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 1997;11:1921-8
   PubMed Web of Science ®Google Scholar
• Buchner M, Fuchs S, Prinz G, Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009;69:5424-32
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009;23:686-97
   PubMed Web of Science ®Google Scholar
• Quiroga MP, Balakrishnan K, Kurtova AV, B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029-37
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-55
   PubMed Web of Science ®Google Scholar
• Baudot AD, Jeandel PY, Mouska X, The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009;28:3261-73
   PubMed Web of Science ®Google Scholar
• Song Z, Lu P, Furman RR, Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 2010;16:587-99
   PubMed Web of Science ®Google Scholar
• Buchner M, Baer C, Prinz G, Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010;115:4497-506
   PubMed Web of Science ®Google Scholar
• Suljagic M, Longo PG, Bennardo S, The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010;116:4894-905
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85
   PubMed Web of Science ®Google Scholar
• Chu DH, Morita CT, Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev 1998;165:167-80
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trumper L, Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750-8, 0041.1-0041.11
   PubMed Web of Science ®Google Scholar
• Lanham S, Hamblin T, Oscier D, Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101:1087-93
   PubMed Web of Science ®Google Scholar
• Kong GH, Bu JY, Kurosaki T, Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. Immunity 1995;2:485-92
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-14
   PubMed Web of Science ®Google Scholar
• Turner M, Schweighoffer E, Colucci F, Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000;21:148-54
   PubMedGoogle Scholar
• Petlickovski A, Laurenti L, Li X, Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005;105:4820-7
   PubMed Web of Science ®Google Scholar
• Chen L, Apgar J, Huynh L, ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005;105:2036-41
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007;109:2032-9
   PubMed Web of Science ®Google Scholar
• Latour S, Chow LM, Veillette A. Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases. J Biol Chem 1996;271:22782-90
   PubMed Web of Science ®Google Scholar
• Laurenti L, Petlickovski A, Rumi C, Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica 2005;90:1533-40
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Schneller F, Bogner C, Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002;100:3741-8
   PubMed Web of Science ®Google Scholar
• Kienle D, Benner A, Krober A, Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006;107:2090-3
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19
   PubMed Web of Science ®Google Scholar
• Leupin N, Cenni B, Novak U, Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL). Br J Haematol 2003;121:97-100
   PubMed Web of Science ®Google Scholar
• Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol 1996;156:4543-54
   PubMed Web of Science ®Google Scholar
• Beraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999;96:429-34
   PubMed Web of Science ®Google Scholar
• Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90
   PubMed Web of Science ®Google Scholar
• Andjelic S, Hsia C, Suzuki H, Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways. J Immunol 2000;165:3860-7
   PubMed Web of Science ®Google Scholar
• Cuni S, Perez-Aciego P, Perez-Chacon G, A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391-400
   PubMed Web of Science ®Google Scholar
• Edelmann J, Klein-Hitpass L, Carpinteiro A, Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res 2008;32:1565-72
   PubMed Web of Science ®Google Scholar
• Fernandis AZ, Prasad A, Band H, Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004;23:157-67
   PubMed Web of Science ®Google Scholar
• Kijima T, Maulik G, Ma PC, Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149-53
   PubMed Web of Science ®Google Scholar
• Niedermeier M, Hennessy BT, Knight ZA, Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113:5549-57
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, PI3Kdelta inhibitor, GS-1101(CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119:1897-900
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117:4323-7
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-12
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Brown JR, CAL-101, An isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116(21):31a
   Web of Science ®Google Scholar
• Stokoe D, Stephens LR, Copeland T, Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997;277:567-70
   PubMed Web of Science ®Google Scholar
• Alessi DR, Andjelkovic M, Caudwell B, Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51
   PubMed Web of Science ®Google Scholar
• Aoki M, Schetter C, Himly M, The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem 2000;275:6267-75
   PubMed Web of Science ®Google Scholar
• Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41
   PubMed Web of Science ®Google Scholar
• Plate JM. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation. Leuk Lymphoma 2004;45:1519-29
   PubMed Web of Science ®Google Scholar
• Cardone MH, Roy N, Stennicke HR, Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9
   PubMed Web of Science ®Google Scholar
• Kops GJ, Burgering BM. Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 2000;197 Pt 4:571-4
   PubMed Web of Science ®Google Scholar
• Hahn-Windgassen A, Nogueira V, Chen CC, Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-9
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
   PubMed Web of Science ®Google Scholar
• Tolcher AW YT, Fearen I, Taylor A, A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009;27(15s Suppl):abstract 3503
   Google Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10
   PubMed Web of Science ®Google Scholar
• Ougolkov AV, Bone ND, Fernandez-Zapico ME, Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007;110:735-42
   PubMed Web of Science ®Google Scholar
• Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004;25:471-80
   PubMed Web of Science ®Google Scholar
• Tsukada S, Saffran DC, Rawlings DJ, Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279-90
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-96
   PubMed Web of Science ®Google Scholar
• Smith CI, Baskin B, Humire-Greiff P, Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994;152:557-65
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Scharenberg AM, Park H, Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996;271:822-5
   PubMed Web of Science ®Google Scholar
• Baba Y, Hashimoto S, Matsushita M, BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci USA 2001;98:2582-6
   PubMed Web of Science ®Google Scholar
• Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 1998;56:683-91
   PubMed Web of Science ®Google Scholar
• Feldhahn N, Rio P, Soh BN, Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci USA 2005;102:13266-71
   PubMed Web of Science ®Google Scholar
• Uckun FM, Waddick KG, Mahajan S, BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science 1996;273:1096-100
   PubMed Web of Science ®Google Scholar
• Vassilev A, Ozer Z, Navara C, Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 1999;274:1646-56
   PubMed Web of Science ®Google Scholar
• Uckun F, Ozer Z, Vassilev A. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress. Br J Haematol 2007;136:574-89
   PubMed Web of Science ®Google Scholar
• Feldhahn N, Klein F, Mooster JL, Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 2005;201:1837-52
   PubMed Web of Science ®Google Scholar
• Mahajan S, Vassilev A, Sun N, Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 2001;276:31216-28
   PubMed Web of Science ®Google Scholar
• Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp Med 1996;184:31-40
   PubMed Web of Science ®Google Scholar
• Fluckiger AC, Li Z, Kato RM, Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J 1998;17:1973-85
   PubMed Web of Science ®Google Scholar
• Imboden JB, Stobo JD. Transmembrane signalling by the T cell antigen receptor. Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. J Exp Med 1985;161:446-56
   PubMed Web of Science ®Google Scholar
• Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993;361:315-25
   PubMed Web of Science ®Google Scholar
• Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem 2001;276:1715-19
   PubMed Web of Science ®Google Scholar
• Mahajan S, Ghosh S, Sudbeck EA, Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999;274:9587-99
   PubMed Web of Science ®Google Scholar
• Uckun FM, Zheng Y, Cetkovic-Cvrlje M, In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002;8:1224-33
   PubMed Web of Science ®Google Scholar
• Tibbles HE, Samuel P, Erbeck D, In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. Arzneimittelforschung 2004;54:330-9
   PubMed Web of Science ®Google Scholar
• Uckun FM, Tibbles H, Venkatachalam T, Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13). Arzneimittelforschung 2007;57:31-46
   PubMed Web of Science ®Google Scholar
• Kim YJ, Sekiya F, Poulin B, Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol 2004;24:9986-99
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Kitaura J, Hata D, Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol 1999;65:286-90
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Schmidt U, The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007;104:13283-8
   PubMed Web of Science ®Google Scholar
• Ponader CS, Buggy JJ, Balakrishnan K, Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119:1182-9
   PubMed Web of Science ®Google Scholar
• Burger JA, O'Brien S, Fowler N, The bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL): an update on ongoing Phase I studies. Blood 2010;116:57a
   Web of Science ®Google Scholar
• Evans E, Aslanian S, Karp R, Bruton's Tyrosine Kinase from Bench to Bedside: Covalently Silencing B Cells with AVL-292. 16th Congress of the European Hematology Association; 2011
   Google Scholar
• Alkan S, Huang Q, Ergin M, Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol 2005;79:97-106
   PubMed Web of Science ®Google Scholar
• Barragan M, de Frias M, Iglesias-Serret D, Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 2006;80:1473-9
   PubMed Web of Science ®Google Scholar
• Barragan M, Campas C, Bellosillo B, Gil J. Protein kinases in the regulation of apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:1865-70
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-7
   PubMed Web of Science ®Google Scholar
• Snowden RT, Sun XM, Dyer MJ, Cohen GM. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 2003;17:1981-9
   PubMed Web of Science ®Google Scholar
• Thomas A, Pepper C, Hoy T, Bentley P. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2004;45:997-1008
   PubMed Web of Science ®Google Scholar
• Abrams ST, Lakum T, Lin K, B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 2007;109:1193-201
   PubMed Web of Science ®Google Scholar
• Escobar-Diaz E, Lopez-Martin EM, Hernandez del Cerro M, AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway. Leukemia 2005;19:572-9
   PubMed Web of Science ®Google Scholar
• Ganeshaguru K, Wickremasinghe RG, Jones DT, Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002;87:167-76
   PubMed Web of Science ®Google Scholar
• Virchis A, Ganeshaguru K, Hart S, A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 2002;3:131-6
   PubMedGoogle Scholar
• Marti GE, Stetler-Stevenson M, Grant ND, Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:2284-92
   PubMed Web of Science ®Google Scholar
• Holler C, Pinon JD, Denk U, PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009;113:2791-4
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40
   PubMed Web of Science ®Google Scholar
• Kawauchi K, Ogasawara T, Yasuyama M. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia. Int J Hematol 2002;75:508-13
   PubMed Web of Science ®Google Scholar
• Smal C, Lisart S, Maerevoet M, Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB. Biochem Pharmacol 2007;73:351-8
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Buhl AM, Klausen P, The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99:1314-19
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Dechow T, Schneller F, Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004;18:1964-70
   Web of Science ®Google Scholar
• Fecteau JF, Bharati IS, O'Hayre M, Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and Mcl-1. Mol Med 2012;18:19-28
   PubMed Web of Science ®Google Scholar
• Messmer D, Fecteau JF, O'Hayre M, Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011;117:882-9
   PubMed Web of Science ®Google Scholar
• Fukuda T, Chen L, Endo T, Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008;105:3047-52
   PubMed Web of Science ®Google Scholar
• Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008;123:1190-5
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Bearss D, Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150-7
   PubMed Web of Science ®Google Scholar
• Raval A, Tanner SM, Byrd JC, Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007;129:879-90
   PubMed Web of Science ®Google Scholar
• Chim CS, Chan WW, Kwong YL. Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias. J Clin Pathol 2008;61:844-7
   PubMed Web of Science ®Google Scholar
• Yankulov KY, Bentley DL. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J 1997;16:1638-46
   PubMedGoogle Scholar
• Lam LT, Pickeral OK, Peng AC, Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2; RESEARCH0041
   Google Scholar
• Tong WG, Chen R, Plunkett W, Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010;28:3015-22
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012-18
   PubMed Web of Science ®Google Scholar
• Boehrer S, Ades L, Braun T, Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008;111:2170-80
   PubMed Web of Science ®Google Scholar
• Morton LM, Curtis RE, Linet MS, Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28:4935-44
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 inhibition: results of a Phase I Study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-96
   PubMed Web of Science ®Google Scholar